Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate the efficacy and safety of ANX005 administered by
intravenous (IV) infusion to participants recently diagnosed with Guillain-Barré Syndrome
(GBS). The total duration of study participation is approximately 6 months.